Amidst the complexity of the human body lies the key to understanding various diseases and their treatments: biomarkers. These biological indicators can reveal the state of health or the progression of a disease, making their discovery crucial in medical research. Biomarker discovery services combine cutting-edge science with an understanding of disease mechanisms to identify these…
Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
Several biotech and pharmaceutical companies are actively involved in researching and developing drugs for Parkinson’s disease. Parkinson’s disease is a neurodegenerative disorder that primarily affects movement. Efforts in this area range from developing therapies for managing symptoms to those targeting the disease’s underlying causes. Here are some notable companies and their approaches: ACADIA Pharmaceuticals: ACADIA…
Scientists have successfully created 3D-printed brain tissue that closely mimics the behavior of natural brain tissue. This development holds great promise for advancing research in neurological and neurodevelopment disorders. The novel 3D-printing technique utilizes a horizontal layering method and a softer bio-ink, enabling the interconnection and formation of networks resembling those found in human brain…
Introduction: The global Neurodegenerative Disease Market is on the cusp of significant expansion, driven by the rising prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis, and Alzheimer’s disease. According to a recent study by MarketDigits, the market is projected to reach USD 69.8 billion by 2030, growing at a robust CAGR of 6.2% during…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
Athira Pharma, Inc. (NASDAQ: ATHA), a leading late-stage biopharmaceutical company dedicated to pioneering small molecules that rejuvenate neurons and decelerate neurodegeneration, has unveiled compelling findings from its SHAPE Phase 2 clinical trial. This trial assessed the potential of fosgonimeton (ATH-1017) in patients grappling with Parkinson’s disease, dementia, and dementia with Lewy bodies. Fosgonimeton Fosgonimeton is a…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
Nimbus Therapeutics LLC, a trailblazing player in the pharmaceutical industry, has recently garnered substantial investment from GV, the investment arm affiliated with tech giant Google. The company, known for licensing drugs to industry giants like Gilead Sciences Inc. and Takeda Pharmaceutical Company Limited and forming strategic partnerships with leaders like Eli Lilly and Company, unveiled…